Filter...

AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesTechnology, Industry, AgricultureInformation ScienceHealth Care

Select a category...

ThrombosisVenous ThrombosisCoronary ThrombosisSinus Thrombosis, IntracranialIntracranial ThrombosisCarotid Artery ThrombosisAnticoagulantsSagittal Sinus ThrombosisPhlebographyIntracranial Embolism and ThrombosisIliac VeinThrombophiliaFemoral VeinUpper Extremity Deep Vein ThrombosisPortal VeinCerebral VeinsHeparinFactor VFibrinolytic AgentsHemostasisHeparin, Low-Molecular-WeightCavernous Sinus ThrombosisBlood CoagulationAntiphospholipid SyndromeVena Cava, InferiorThromboembolismPlatelet Aggregation InhibitorsLateral Sinus ThrombosisBleeding TimeThrombectomyFibrin Fibrinogen Degradation ProductsStentsProtein S DeficiencyTreatment OutcomePlatelet AggregationMesenteric VeinsSubclavian VeinDrug-Eluting StentsProthrombinRisk FactorsPopliteal VeinJugular VeinsBlood PlateletsVenous ThromboembolismHemorrhageAntibodies, AntiphospholipidProtein C DeficiencyCranial SinusesActivated Protein C ResistanceLupus Coagulation InhibitorPlatelet ActivationThromboplastinTime FactorsThrombolytic TherapyWarfarinFollow-Up StudiesRenal VeinsSplenic VeinUltrasonography, Doppler, DuplexBudd-Chiari SyndromeAntithrombin III DeficiencyRetrospective StudiesFibrinolysisAxillary VeinMesenteric Vascular OcclusionProtein CPostthrombotic SyndromeAspirinCatheterization, Central VenousGraft Occlusion, VascularFibrinVena Cava FiltersFibrinogenPostphlebitic SyndromeAntithrombinsArteriovenous Shunt, SurgicalProspective StudiesTiclopidinePartial Thromboplastin TimeRecurrenceTomography, X-Ray ComputedBlood Coagulation TestsAngioplasty, Balloon, CoronarySirolimusCatheters, IndwellingCoronary RestenosisAntibodies, AnticardiolipinStockings, CompressionThrombocythemia, EssentialCatheterization, PeripheralBlood Coagulation FactorsEnoxaparinVascular PatencyVeinsBlood Coagulation DisordersAcute DiseaseThrombocytopeniaSuperior Sagittal SinusProsthesis DesignProtein S

Deep vein thrombosis and pulmonary embPulmonary embolismVenousAcuteRecurrentPathophysiologyPlateletCavaThrombolysisPatientsOcclusionClinicalRisk factorsPresentCases

Deep vein thrombosis and pulmonary emb1

• A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. (medscape.com)

Pulmonary embolism1

• Colloquially known as blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) are forms of venous thromboembolism (VTE). (medscape.com)

Venous6

• Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young. (medscape.com)
• Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, chemotherapy, use of erythropoiesis-stimulating agents (ESAs) and new molecular-targeted therapies such as antiangiogenic agents. (oncologynurseadvisor.com)
• 1 In 1865, another French physician Armand Trousseau reported an association between gastric cancer and venous thrombosis. (oncologynurseadvisor.com)
• Percutaneous transcatheter treatment of patients with deep venous thrombosis (DVT) consists of thrombus removal with catheter-directed thrombolysis, mechanical thrombectomy, angioplasty, and/or stenting of venous obstructions. (medscape.com)
• The goals of endovascular therapy include reducing the severity and duration of lower-extremity symptoms, preventing PE, diminishing the risk of recurrent venous thrombosis, and preventing postthrombotic syndrome (PTS). (medscape.com)
• For more information, see Deep Venous Thrombosis . (medscape.com)

Acute2

• Acute basilar artery thrombosis is associated with a poor prognosis. (medscape.com)
• In situations in which the occlusion is secondary to atherosclerosis, acute thromboses of the artery are generally asymptomatic. (medscape.com)

Recurrent1

• Continuation of therapy beyond that should be based on the risk for recurrent thrombosis versus the risk of major bleeding for each individual patient. (oncologynurseadvisor.com)

Pathophysiology1

• This review will focus on the epidemiology and pathophysiology of cancer-associated thrombosis, risk factors, and new predictive biomarkers for VTE as well as discuss novel prevention and management regimens of VTE in cancer according to published guidelines. (oncologynurseadvisor.com)

Platelet2

• If VITT is suspected , perform immediate CBC with platelet count and imaging for thrombosis based on symptoms. (hematology.org)
• This disruption precipitates platelet deposition in the area, with resulting thrombosis. (medscape.com)

Cava3

• Alkhouli M, Shafi I, Bashir R. Inferior vena cava filter thrombosis and suprarenal caval stenosis: a double whammy. (medscape.com)
• Congenital anomalies of the inferior vena cava revealed on CT in patients with deep vein thrombosis. (medscape.com)
• Sitwala PS, Ladia VM, Brahmbhatt PB, Jain V, Bajaj K. Inferior vena cava anomaly: a risk for deep vein thrombosis. (medscape.com)

Thrombolysis1

• Although outcomes continue to be poor in patients with basilar artery thrombosis, advances in pharmacologic and mechanical thrombolysis and in endovascular therapy may reduce the mortality and disability rates associated with this disease. (medscape.com)

Patients2

• Because patients with inferior vena caval (IVC) thrombosis (IVCT) may present with a variety of signs and symptoms, the diagnosis can be challenging. (medscape.com)
• Emerging data have enhanced our understanding of cancer-associated thrombosis, a major cause of morbidity and mortality in patients with cancer. (oncologynurseadvisor.com)

Occlusion2

• Given the anatomy of the posterior circulation and the circle of Willis, the clinical manifestations of basilar artery thrombosis depend on the location of the occlusion, the extent of the thrombus, and the collateral flow. (medscape.com)
• [ 1 ] Sudden occlusion from emboli followed by thrombosis of the artery is common in the population with signs of significant atherosclerotic disease. (medscape.com)

Clinical1

• The clinician must have a profound awareness of the associated elements that make up the clinical complex of congenital vena caval thrombosis in order to avoid diagnostic and treatment pitfalls. (medscape.com)

Risk factors1

• The risk factors for basilar artery thrombosis are the same as those seen generally in stroke . (medscape.com)

Present1

• If thrombocytopenia or thrombosis are present, recommend urgent consultation from hematologist with expertise in hemostasis. (hematology.org)

Cases1

• On April 13, 2021, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) suggested pausing administration of the AD26.COV2.S Johnson & Johnson (JJ) vaccine to allow investigation of several cases of severe thrombosis with thrombocytopenia occurring post-vaccination. (hematology.org)